Search results
Results From The WOW.Com Content Network
Website. sanofigenzyme .com. Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing ...
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [ 7][ 8]
Paris-based Sanofi's CEO Chris Viehbacher provided a possible price range of $69 to $80 a share when he met the Genzyme's CEO Henri Termeer at a Sept. 20 meeting. Termeer declined to agree to the ...
Paris-based pharmaceutical Sanofi-Aventis (SNY) has extended the deadline for its tender offer for Cambridge, Mass.-based biotech Genzyme (GENZ) by six weeks, from Dec. 10 to Jan. 21, 2011. All ...
This collaboration comes after Novo Nordisk , Eli Lilly and Sanofi pledged in March to lower the list prices of many of their insulin products by 70%-78% later in the year or in 2024. GoodRx to ...
The following are list of bioCSL flu vaccine brands: [31] Trivalent. Afluria, also marketed as Enzira, Fluvax, and Nilgrip in various different markets. Agrippal, also marketed as Begripal, Fluazur, Sandovac, Agriflu, and Chiroflu in various different markets. Fluad, [32] [1] also marketed as Chiromas in Spain.
"A key strategy for Sanofi-Aventis is to transform its R&D model and discover new medicines through the use of novel technologies and innovative partnerships," said Sanofi's R&D boss, Dr. Marc Cluzel.